Whole Body Positron Emission Tomography in Oncology

  • Ulrich Feine
  • Roland Lietzenmayer
  • Wolfgang Müller-Schauenburg
Part of the Developments in Nuclear Medicine book series (DNUM, volume 28)


It has been shown in numerous studies that malignant tumors can be identified by increased trapping of 18F fluorodeoxyglucose (FDG) [1]. The reported sensitivity of positron-emission-tomography (PET) with FDG varies between 80–90%. Until 1993 the maximum field of view (FOV) of commercially available PET-scanners was 5–10 cm confining the use of PET to defined body regions. Recently high resolution PET-scanners with 15 cm FOV have been developed. Sequential scanning of 5–11 FOV’s allows to perform whole body (WB) scans - head to knee or head to foot - in 30–55 minutes (Fig.1) taking maximum profit of the favourable properties of FDG for tumor diagnosis and staging.


Thyroid Cancer Bone Metastasis Thyroid Carcinoma Differentiate Thyroid Cancer Follicular Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Strauss LG, Conti PS. The application ofPET in clinical oncology.J.Nucl.Med. 1991, 32: 623–648.PubMedGoogle Scholar
  2. 2.
    Tse NY, Hawkins RA, Zimmer MJ, Dahlbaum M, et al 1992.:The application of positron emission tomography imaging with fluorodeoxygluose to the evaluation of breast disease. AnnSurg 1992, 216 (1): 27–34.Google Scholar
  3. 3.
    Hawkins RA, Hoh C, Glapsy J, et al and Phelps ME: The role of positron emissiontomography in oncology and other whole body application. Sem.Nucl.Med. 22 (4) 1992: 268–284.CrossRefGoogle Scholar
  4. 4.
    Hoh CK, Hawkins RA, Glaspy JA, Dahlborn M, Tse NY, et al: Cancer detection withwhole body PET using 18 F-fluoro-deoxyclucose. J.Comp.Assist.Tomogr. 1993; 17 (4): 582–589.CrossRefGoogle Scholar
  5. 5.
    Rege SD, Hoh CK, Glapsy JA, Abcrle DR, Dahlbom M et al.: Imaging of pulmonarymass lesions with whole body positron emission tomography and fluorodeoxyglucose.Cancer 1993: 1, 72(1) 82–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Karlan BY, Hawkins R, Hoh CK, Lee M et al: Whole body positron emission tomography with 2–18 F fluor-desoxyglucose can detect recurrent ovarian carcinoma. Gynecol. Oncol 1993, 51 (2): 175–181.Google Scholar
  7. 7.
    Yao WJ, Hoh CK, Glapsy JA, et al: Whole body FDG PET imaging for staging ofmalignant melanoma. J.Nucl Med. 1994; 34: 8 P.Google Scholar
  8. 8.
    Joensuu H, Ahonen A.Imaging ofmetastases ofthyroid carcinoma with fluorine-18fluoro-deoxyglucose. J.Nucl.Med. 1987, 28: 910–914.PubMedGoogle Scholar
  9. 9.
    Joensuu H, Ahonen A, Klemi PJ.18-F-fluorodeoxyglucose imaging in preoperativediagnosis of thyroid malignancy. Eur.J.Nucl.Med. 1988, 13: 502–506.PubMedCrossRefGoogle Scholar
  10. 10.
    Schmidt D, Herzog H, Langen KJ, Müller-Gärtner HW. Glucose metabolism in thyroid cancer metastases. A pilot study using 18-fluoro-2-deoxyglucose and positron emission tomography. Exp.Clin.Endocrinol. 1994, 102: 51–54.CrossRefGoogle Scholar
  11. 11.
    Bömer AR, Voth E, Schicha H. 18-FDG-PET bei Patienten mit immunogener Hyper thyreose vor Radiojodtherapie. Nucl.Med. 1994, 33 A 81.Google Scholar
  12. 12.
    Di Chiro G. Positron emission tomography using 18-F-fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest.Radiol. 1987, 22: 360–371.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Ulrich Feine
  • Roland Lietzenmayer
  • Wolfgang Müller-Schauenburg

There are no affiliations available

Personalised recommendations